Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 11/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.47 |
| ▸ | CDK2 | P24941 | 11/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 11/20 | 0.47 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551968 | 0.87 | CDC7 (0.52) | CDC7CCNE1CDK2DBF4RXFP1 | |
| SCHEMBL1962537 | 0.85 | PIK3CB (0.47) | CDC7CCNE1CDK2DBF4PDCD1 | |
| SCHEMBL1551977 | 0.73 | KDM4E (0.41) | EGFR | |
| SCHEMBL16157018 | 0.71 | CDC7 (0.61) | CDC7CCNE1CDK2DBF4QPCT | |
| SCHEMBL12550883 | 0.71 | CDC7 (0.58) | CDC7CCNE1CDK2DBF4QPCT | |
| SCHEMBL1961463 | 0.69 | MAPT (0.40) | CDC7CCNE1CDK2DBF4PDCD1 | |
| SCHEMBL1960827 | 0.67 | CDC7 (0.57) | CDC7CCNE1CDK2DBF4QPCT | |
| SCHEMBL8514369 | 0.67 | KDM4E (0.53) | RXFP1 | |
| SCHEMBL12550890 | 0.67 | CDC7 (0.49) | CDC7CCNE1CDK2DBF4QPCT | |
| SCHEMBL21801477 | 0.65 | CDC7 (0.48) | CDC7CCNE1CDK2DBF4QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377975-B2 | Oxadiazole derivatives for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-02-19 | — | — | US | disclosed |
| US-20110139654-A1 | OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110139654-A1 | OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | PFKL, RXFP3, OXA1L | CDC7 967/4885CCNE1 685/4885CDK2 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.